We previously reported that angiotensin converting enzyme inhibitors (ACEIs) decrease the rate of cognitive decline in elderly patients with hypertension, but their impact on patients with Alzheimer's disease (AD) is not known. A total of 62 elderly patients with AD were enrolled, and 52 completed the study for 6 months. Mini-Mental Status Examination (MMSE), Clock Draw Test (CDT), working memory (Digit Ordering), Instrumental Activities of Daily Living (IADL) scale, and the Screen for Caregiver Burden (SCB) were collected at baseline, 3 months, and 6 months. AD patients receiving ACEI (N = 15) demonstrated a slower rate of decline in digit forward (P = .003) and IADL scale (P = .003) and an improved measure of caregiver burden (P = .04) but not MMSE (P =.15) or CDT (P =.9) compared with those not receiving ACEI after adjusting for other risk factors. This study suggests that use of ACEI in AD patients is associated with slower rate of AD progression. A randomized clinical trial is needed to confirm our finding.
Whitmer RA, Sidney S., Selby J., Johnston SC, Yaffe K.Midlife cardiovascular risk factors and risk of dementia in late life. Neurology. 2005;64:277-281.
2.
Braszko JJ, Karwowska-Polecka W., Halicka D., Gard PRCaptopril and enalapril improve cognition and depressed mood in hypertensive patients. J Basic Clin Physiol Pharmacol. 2003;14:323-343.
3.
Staessen JA, Thijs L., Fagard R., et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA.1999; 282:539-546.
4.
Iadecola C., Gorelick PBConverging pathogenic mechanisms in vascular and neurodegenerative dementia . Stroke. 2003;34:335-337.
5.
Skoog I., Lernfelt B., Landahl S., et al. 15-year longitudinal study of blood pressure and dementia. Lancet. 1996; 347:1141-1145.
6.
Bellew KM, Pigeon JG, Stang PE, Fleischman W., Gardner RM, Baker WWHypertension and the rate of cognitive decline in patients with dementia of the Alzheimer type. Alzheimer Dis Assoc Disord. 2004;18: 208-213.
7.
Goldstein AO , Carey TS, Levis D., Madson S., Bernstein J.Variations in hypertension control in indigent rural primary care clinics in North Carolina. Arch Fam Med . 1994;3:514-519.
8.
Savaskan E.The role of the brain renin-angiotensin system in neurodegenerative disorders . Curr Alzheimer Res. 2005;2:29-35.
9.
Savaskan E., Hock C., Olivieri G., et al. Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer's dementia. Neurobiol Aging . 2001;22:541-546.
10.
Lehmann DJ, Cortina-Borja M., Warden DR, et al. Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer's disease. Am J Epidemiol.2005;162:305-317.
11.
Ando HJ, Zhou M., Macova M., Imboden H., Saavedra JM. Angiotensin II AT1 receptor blockade reverses pathological hypertrophy and inflammation in brain microvessels of spontaneously hypertensive rats . Stroke. 2004;35:1726-1731.
12.
Barnes JM, Barnes NM, Costall B., Horovitz ZP, Naylor RJ. Angiotensin II inhibits the release of [3H]acetylcholine from rat entorhinal cortex in vitro. Brain Res. 1989 ;491: 136-143.
13.
Zuccala G., Onder G., Marzetti E., et al. Use of angiotensin-converting enzyme inhibitors and variations in cognitive performance among patients with heart failure. Eur Heart J.2005;26:226-233.
14.
Dufouil C., Chalmers J., Coskun O., et al. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation. 2005;112: 1644-1650.
15.
Fransen M., Anderson C., Chalmers J., et al. Effects of a perindopril-based blood pressure-lowering regimen on disability and dependency in 6105 patients with cerebrovascular disease: a randomized controlled trial. Stroke. 2003 ;34:2333-2338.
16.
Rozzini L., Chilovi BV, Bertoletti E., et al. Angiotensin converting enzyme (ACE) inhibitors modulate the rate of progression of amnestic mild cognitive impairment. Int J Geriatr Psychiatry. 2006;21:550-555.
17.
Hajjar I., Catoe H., Sixta S., et al. Cross-sectional and longitudinal association between antihypertensive medications and cognitive impairment in an elderly population. J Gerontol A Biol Sci Med Sci.2005;60:67-73.
18.
Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001; 56:1143-1153.
19.
Bassuk SS, Glass TA, Berkman LFSocial disengagement and incident cognitive decline in community-dwelling elderly persons. Ann Intern Med. 1999;131: 165-173.
20.
Charlson ME, Pompei P., Ales KL, MacKenzie CRA new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
21.
Lawton MP, Brody EMAssessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179-186.
22.
Vitaliano PP, Russo J., Young HM, Becker J., Maiuro RDThe screen for caregiver burden. Gerontologist. 1991; 31:76-83.
23.
Folstein MF , Folstein SE, McHugh PR“Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12: 189-198.
24.
Sunderland T., Hill JL, Mellow AM, et al. Clock drawing in Alzheimer's disease. A novel measure of dementia severity. J Am Geriatr Soc.1989;37:725-729.
25.
MacDonald MC , Almor A., Henderson VW, Kempler D., Andersen ESAssessing working memory and language comprehension in Alzheimer's disease. Brain Lang. 2001;78:17-42.
Littell RC, Henry PR, Ammerman CBStatistical analysis of repeated measures data using SAS procedures. J Anim Sci. 1998;76:1216-1231.
28.
Munakata M. , Imai Y., Abe K., et al. Assessment of age-dependent changes in circadian blood pressure rhythm in patients with essential hypertension . J Hypertens.1991;9:407-415.
29.
Ohrui T., Tomita N., Sato—Nakagawa T., et al. Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology. 2004;63:1324-1325.
30.
Carter CS, Onder G., Kritchevsky SB, Pahor M.Angiotensin-converting enzyme inhibition intervention in elderly persons: effects on body composition and physical performance. J Gerontol A Biol Sci Med Sci. 2005;60:1437-1446.
31.
Di Bari M., van de Poll-Franse LV, Onder G., et al. Antihypertensive medications and differences in muscle mass in older persons: the Health, Aging and Body Composition Study. J Am Geriatr Soc. 2004;52:961-966.
32.
Onder G., Penninx BW, Lapuerta P., et al. Change in physical performance over time in older women: the Women's Health and Aging Study. J Gerontol A Biol Sci Med Sci. 2002;57:M289-M293.
33.
Lipsitz LA, Gagnon M., Vyas M., et al. Antihypertensive therapy increases cerebral blood flow and carotid distensibility in hypertensive elderly subjects. Hypertension . 2005;45:216-221.
34.
von Haehling S., Sandek A., Anker SDPleiotropic effects of angiotensin-converting enzyme inhibitors and the future of cachexia therapy. J Am Geriatr Soc. 2005;53:2030-2031.
35.
Cesari M., Kritchevsky SB, Baumgartner RN, et al. Sarcopenia, obesity, and inflammation—results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors Study. Am J Clin Nutr.2005;82:428-434.
36.
Hemming ML, Selkoe DJAmyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem. 2005; 280:37644-37650.
37.
Eckman EA, Adams SK, Troendle FJ, et al. Regulation of steady-state beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme. J Biol Chem.2006;281: 30471-30478.
38.
Ellul J., Archer N., Foy CM, et al. The effects of commonly prescribed drugs in patients with Alzheimer's disease on the rate of deterioration. J Neurol Neurosurg Psychiatry . 2007;78:233-239.
39.
Glynn RJ, Beckett LA, Hebert LE, Morris M C., Scherr PA, Evans DACurrent and remote blood pressure and cognitive decline. JAMA.1999;281:438-445.
40.
McLaren AT, Allen J., Murray A., Ballard CG, Kenny RACardiovascular effects of donepezil in patients with dementia. Dement Geriatr Cogn Disord. 2003;15:183-188.
